RE: Seed Clinical Trials Presented6 Jun 2024 08:53
I agree. A pbx rns on this would have provided a boost to the flagging share price. I hope they atleast mention it in the results whenever they are announced.
Revenue excluding sweetbiotix and microbiome modulators won't be anywhere close to the £3m. Likely you say 1 full year with Morepen won't synchronise with the OptiBiotix full year.
Based on one of the forecast slides, I'm expecting close to 1.5m.
We know the standard royalty % with the US partner is 5% plus another 5% for the MTA partners. I think it's safe to assume that OptiBiotix royalty with DSM Firmenich is 5%.
The actual text was > 100k tonnes and this is for only DSM Firmenich.
The US partner will most likely have similar forecast with any few of the big 11 global MTA partners signing up for sweetbiotix. I think this is in the early stages of a major re-rate of the sp.